Andromeda in Early Negotiations with American Pharma Company
Israel's Clal Biotechnology Industries said its subsidiary Andromeda Biotech is in early talks to be sold to an American drug company for a price that could reach hundreds of millions of dollars. Andromeda signed a memorandum of understanding to be sold to the unnamed firm, according to Clal, which owns 96 percent of Andromeda. Read the full story